Literature DB >> 17828401

The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer.

Jung-Myun Kwak1, Byung-Wook Min, Ju-Han Lee, Jong-Sang Choi, Sun-Il Lee, Sung-Soo Park, Jin Kim, Jun-Won Um, Seon-Han Kim, Hong-Young Moon.   

Abstract

PURPOSE: The significance of liver intestine-cadherin as a potential marker has been growing in the field of oncology, because of its unique features compared with classic cadherins. We investigated the coexpression patterns of E-cadherin and liver intestine-cadherin in colorectal cancer, and determined whether differences in expression patterns were associated with clinicopathologic parameters and also which relationship between these two adhesion molecules existed in colorectal cancer.
METHODS: Expression pattern of E-cadherin and liver intestine-cadherin was investigated immunohistochemically in 207 colorectal cancers along with clinicopathologic parameters.
RESULTS: Reduced expression of liver intestine-cadherin was detected in 51 percent (n = 105) of tumors. Such expression was found to be associated with tumoral dedifferentiation (P = 0.015) and in a multivariate analysis was associated with a significant worse overall survival after adjustment for tumor stage, differentiation, and E-cadherin status (hazard ratio, 1.951; 95 percent confidence interval, 1.06-3.592; P = 0.032). Fifteen percent (n = 32) of tumors showed reduced expression of E-cadherin and had relationship with tumoral dedifferentiation (P < 0.001), lymph node metastasis (P = 0.004), and advanced stage (P = 0.029). Reduced expression of E-cadherin was associated with short overall survival (P = 0.028); however, in a multivariate analysis, it was not statistically significant.
CONCLUSIONS: Reduced expression of liver intestine-cadherin had a significant correlation with tumoral dedifferentiation and short overall survival in this series. In addition, early and frequent loss of liver intestine-cadherin expression might be a more sensitive indicator than E-cadherin to predict more aggressive tumoral behavior.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828401     DOI: 10.1007/s10350-007-9034-1

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  21 in total

1.  Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis.

Authors:  Xiaobing Chen; Yongsheng Wang; Hongping Xia; Qiwu Wang; Xiaochun Jiang; Zihong Lin; Yuedong Ma; Yang Yang; Minghua Hu
Journal:  Mol Biol Rep       Date:  2012-02-07       Impact factor: 2.316

Review 2.  Cadherins down-regulation: towards a better understanding of their relevance in colorectal cancer.

Authors:  Lorena Losi; Tommaso Zanocco-Marani; Alexis Grande
Journal:  Histol Histopathol       Date:  2020-06-22       Impact factor: 2.303

3.  Blockade of proliferation and migration of gastric cancer via targeting CDH17 with an artificial microRNA.

Authors:  Jin Zhang; Qi-Sheng Liu; Wei-Guo Dong
Journal:  Med Oncol       Date:  2011-06       Impact factor: 3.064

4.  Single nucleotide polymorphisms in the CDH17 gene of colorectal carcinoma.

Authors:  Ren-Yin Chen; Juan-Juan Cao; Juan Chen; Jian-Ping Yang; Xiao-Bo Liu; Guo-Qiang Zhao; Yu-Feng Zhang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

5.  Dog as model for down-expression of E-cadherin and beta-catenin in tubular epithelial cells in renal fibrosis.

Authors:  Luca Aresu; Maria Pia Rastaldi; Paola Pregel; Federico Valenza; Enrico Radaelli; Eugenio Scanziani; Massimo Castagnaro
Journal:  Virchows Arch       Date:  2008-10-24       Impact factor: 4.064

6.  Clinical applications of gene expression in colorectal cancer.

Authors:  Elrasheid A H Kheirelseid; Nicola Miller; Kah Hoong Chang; Mary Nugent; Michael J Kerin
Journal:  J Gastrointest Oncol       Date:  2013-06

Review 7.  Involvement of liver-intestine cadherin in cancer progression.

Authors:  Masaaki Takamura; Satoshi Yamagiwa; Yasunobu Matsuda; Takafumi Ichida; Yutaka Aoyagi
Journal:  Med Mol Morphol       Date:  2013-01-10       Impact factor: 2.309

8.  Cadherin 17 is frequently expressed by 'sclerosing variant' pancreatic neuroendocrine tumour.

Authors:  Adam Johnson; Jesse P Wright; Zhiguo Zhao; Tatsuki Komaya; Alexander Parikh; Nipun Merchant; Chanjuan Shi
Journal:  Histopathology       Date:  2014-10-28       Impact factor: 5.087

9.  An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1.

Authors:  Zsuzsanna Pap; Zoltán Pávai; Lóránd Dénes; Ilona Kovalszky; János Jung
Journal:  Pathol Oncol Res       Date:  2009-03-01       Impact factor: 3.201

10.  Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma.

Authors:  Ling Xiao Liu; Nikki P Lee; Vivian W Chan; Wen Xue; Lars Zender; Chunsheng Zhang; Mao Mao; Hongyue Dai; Xiao Lin Wang; Michelle Z Xu; Terence K Lee; Irene O Ng; Yangchao Chen; Hsiang-fu Kung; Scott W Lowe; Ronnie T P Poon; Jian Hua Wang; John M Luk
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.